Cambridge, Mass.-based Nuvalent, Inc., which is focused on developing precision therapies for kinase targets in oncology, made its debut on the Nasdaq Exchange this morning, a mere seven months after emerging from stealth mode.
The company raised approximately $165.75 million from the sale of 9,750,000 shares of common stock at $17 per share. The stock is trading on the Nasdaq under the ticker symbol “NUVL.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,